Stock listing

NASDAQ:YMAB Y mAbs Therapeutics Stock

Follow Y mAbs Therapeutics into a list and get an email when it puts out news.

Last close · NASDAQ:YMAB

$8.61 USD

Close on Sep 16, 2025 · No longer trades

Sep 21, 2018 to last close -64.1% · weekly closes, Sep 21, 2018 – Sep 16, 2025
Lowest – highest close
$2.83 – $54.26 USDSince Sep 21, 2018 · lowest Mar 22, 2023 · highest Dec 17, 2020

Delisted NASDAQ:YMAB no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.

Ticker
NASDAQ:YMAB
Asset type
Stock
Exchange
NASDAQ
Currency
USD

Y mAbs Therapeutics on 6ix

Calls
17 calls with a replay · 17 with a transcript · latest Aug 8, 2025
Decks
8 decks · latest May 28, 2025

Events

CallWhenStatus
Y mAbs Therapeutics (YMAB) Q2 2025 Earnings CallFri, Aug 08, 2025 · 8:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q1 2025 Earnings CallTue, May 13, 2025 · 8:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q4 2024 Earnings CallTue, Mar 04, 2025 · 8:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q3 2024 Earnings CallFri, Nov 08, 2024 · 8:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q2 2024 Earnings CallMon, Aug 12, 2024 · 8:30 AM ETReplay
Y mAbs Therapeutics (YMAB) Q1 2024 Earnings CallWed, May 08, 2024 · 8:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q4 2023 Earnings CallFri, Mar 01, 2024 · 8:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q3 2023 Earnings CallTue, Nov 14, 2023 · 9:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q2 2023 Earnings CallFri, Aug 11, 2023 · 9:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q1 2023 Earnings CallTue, May 09, 2023 · 9:00 AM ETReplay
All 17 calls
CallWhenStatus
Y mAbs Therapeutics (YMAB) Q4 2022 Earnings CallFri, Mar 31, 2023 · 9:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q3 2022 Earnings CallTue, Nov 08, 2022 · 4:00 PM ETReplay
Y mAbs Therapeutics (YMAB) Q2 2022 Earnings CallTue, Aug 09, 2022 · 9:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q1 2022 Earnings CallTue, May 10, 2022 · 9:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q4 2021 Earnings CallFri, Feb 25, 2022 · 9:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q3 2021 Earnings CallFri, Nov 05, 2021 · 9:00 AM ETReplay
Y mAbs Therapeutics (YMAB) Q1 2021 Earnings CallFri, May 07, 2021 · 9:00 AM ETReplay

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (May 2025)Technical49 slidesMay 28, 2025
Q1 2025 Earnings PresentationEarnings17 slidesMay 13, 2025
Q4 2024 Earnings PresentationEarnings21 slidesMar 4, 2025
Q3 2024 Earnings PresentationEarnings20 slidesNov 8, 2024
Q2 2024 Earnings PresentationEarnings20 slidesAug 12, 2024
Q1 2024 Earnings PresentationEarnings20 slidesMay 8, 2024
Q4 2023 Earnings PresentationEarnings21 slidesMar 1, 2024
Corporate Update (January 2024)Corporate update25 slidesJan 9, 2024

Open Decks

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Healy
Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); ArriVent BioPharma, Inc. (Director · Since at least Jan 25, 2024); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Coherus Oncology, Inc. (Director · May 22, 2019 – Jan 7, 2022 · Past); Natera, Inc. (Director · Sep 14, 2018 – Apr 25, 2025 · Past)
Director · Since at least Jun 12, 2019
David Gill
Other companies: Telix Pharmaceuticals Limited (Chair & Independent Non-Executive Director · Since Apr 2, 2026); Evolus, Inc. Common Stock (Director · Since at least Feb 12, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Ocugen, Inc. (Director · Dec 9, 2016 – Jun 15, 2018 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past)
Director · Since at least Sep 20, 2018
Laura J. Hamill
Other companies: Fate Therapeutics, Inc. (Board Member · Since at least Jun 12, 2026); Jazz Pharmaceuticals plc (Director, BB Biotech, Fate Therapeutics Inc., and Unchained Labs · Since at least Jul 25, 2024); Scilex Holding Company (Director · Nov 10, 2022 – Jan 17, 2023 · Past); Pardes Biosciences Inc (Director · Dec 23, 2021 – Aug 31, 2023 · Past); Acceleron Pharma Inc (Director · Sep 15, 2020 – Nov 19, 2021 · Past); AnaptysBio, Inc. (Director · Sep 24, 2019 – Jan 6, 2023 · Past); Gilead Sciences, Inc. (EVP, Worldwide Commercial Ops · Sep 10, 2018 – May 8, 2019 · Past)
Director · Since at least Jun 11, 2020
Peter P Pfreundschuh
Other companies: Voyager Therapeutics, Inc. (Chief Financial Officer · Sep 19, 2022 – Feb 21, 2024 · Past); Korro Bio, Inc. (Chief Financial Officer · Dec 1, 2020 – Feb 18, 2022 · Past); UroGen Pharma Ltd. (Chief Financial Officer · Jan 1, 2019 – Oct 15, 2020 · Past); Sucampo Pharmaceuticals Inc (CFO · Mar 20, 2017 – Feb 13, 2018 · Past); Immunomedics Inc (Chief Financial Officer · Aug 20, 2015 – Aug 20, 2015 · Past)
EVP, CFO and Treasurer · Since at least Jun 28, 2024
Mary Tagliaferri
Other companies: ADARx Pharmaceuticals, Inc. (Chief Medical Officer and SVP at Nektar Therapeutics · Since at least Sep 24, 2026); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Enzo Biochem Inc (Director · Nov 17, 2020 – Jan 31, 2024 · Past)
Director · Feb 29, 2024 – Jun 11, 2024 · Past
Gérard Ber
Other companies: Lantheus Holdings, Inc. (Director · Since at least May 6, 2022)
Director · Jul 15, 2022 – Jun 10, 2024 · Past
Michael J Rossi
Other companies: Mirion Technologies, Inc. (Medical Group President · Nov 1, 2023 – Nov 1, 2023 · Past)
PRESIDENT & CEO, Director · Since at least Nov 6, 2023
Ashu TyagiDirector · Since at least Sep 20, 2018
Biotech ApS WGDirector · Since at least May 15, 2023
Bo KruseEVP, CFO, SECRY & TREAS. · Sep 20, 2018 – May 30, 2024 · Past
All 24 people
PersonSeat
Douglas J GentilcoreSVP, Danyelza Bus. Unit Head · Since at least Jan 7, 2025
Gregory S RaskinDirector · Sep 20, 2018 – Aug 29, 2019 · Past
Johan Wedell-WedellsborgDirector · Since at least Sep 20, 2018
John LaRoccaSVP, General Counsel & Secry · Since at least Sep 16, 2025
Joris WilmsSVP & CHIEF OPERATING OFFICER · Since at least Sep 20, 2018
Mahiuddin AhmedSr. VP and CSO · Jan 1, 2020 – May 26, 2020 · Past
Michael BuschleDirector · Sep 20, 2018 – Sep 20, 2018 · Past
Pedro Claus Juan Moller-SanDirector and CEO, Director · Sep 20, 2018 – Dec 14, 2021 · Past
Philip Karl HermanSVP & CCO · Jan 1, 2020 – Dec 15, 2020 · Past
Steen LisbySVP & CHIEF SCIENTIFIC OFFICER · Jan 18, 2024 – Jan 18, 2024 · Past
Susan Laura SmithSVP & CHIEF COMMERCIAL OFFICER · Dec 14, 2021 – Mar 5, 2024 · Past
Thomas GadCHIEF BUSINESS OFFICER, Director · Since at least Sep 20, 2018
Torben Lund-HansenSVP & CHIEF TECHNICAL OFFICER · Apr 26, 2022 – Aug 28, 2024 · Past
Vignesh RajahSVP & CHIEF MEDICAL OFFICER · Jun 2, 2020 – Mar 5, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Y mAbs Therapeutics.